ICD-10-CM Billable Code

C81.30

Lymphocyte depleted Hodgkin lymphoma, unspecified site

Clinical Classification Guidelines

Medical Intelligence & Overview

Lymphocyte Depleted Hodgkin Lymphoma is a rare and aggressive form of Hodgkin lymphoma, a type of cancer that originates in the lymphatic system. This particular subtype, classified under ICD-10 code C81.30, is characterized by a reduced number of lymphocytes within the tumor. It can develop in various parts of the body, and its diagnosis requires careful medical evaluation. Due to its aggressive nature, early recognition and treatment are important, although this overview is intended for informational purposes only.

Causes & Symptoms

Clinical Causes: Genetic mutations that affect lymphocyte development Environmental factors, such as exposure to certain chemicals or radiation Immunosuppression conditions, including HIV/AIDS or post-transplant immunosuppressive therapy Certain viral infections, like Epstein-Barr Virus (EBV), have been associated, though not conclusively causative

Key Symptoms: Swelling or painless lumps in the lymph nodes, commonly in the neck, chest, or underarms Persistent fever without an apparent infection Unexplained weight loss Severe night sweats Fatigue and weakness Itching skin Shortness of breath or cough if the chest is affected Abdominal pain or swelling when the disease involves abdominal lymph nodes

Diagnostic & Treatment

Diagnosis Path: Diagnosing Lymphocyte Depleted Hodgkin Lymphoma involves several steps. Healthcare providers often rely on a combination of procedures including: - Physical Examination: Checking for enlarged lymph nodes and other signs. - Imaging Tests: Chest X-ray, CT scans, or PET scans to identify affected areas. - Biopsy: A tissue sample from a lymph node or other affected site is examined microscopically for characteristic cancer cells. - Laboratory Tests: Blood tests to evaluate overall health and detect abnormalities. - Immunohistochemistry and Molecular Studies: Additional tests to identify specific proteins or genetic features of the lymphoma. Accurate diagnosis is essential to determine the subtype and guide effective treatment options.

Treatment Protocols: Treatment approaches for Lymphocyte Depleted Hodgkin Lymphoma typically involve aggressive therapy due to its rapid progression. These may include: - Chemotherapy: Usually the mainstay of treatment, often with combinations such as ABVD or escalated BEACOPP protocols. - Radiation Therapy: Used in some cases to target localized disease. - Stem Cell Transplantation: Considered for patients who do not respond to initial therapy or relapse. - Targeted Therapies: Newer drugs targeting specific molecules involved in lymphoma growth are being explored. - Supportive Care: Managing symptoms and side effects, including infection prevention and nutritional support. Because of the complexity and severity of this lymphoma type, treatment is generally coordinated by a team of specialists in hematology and oncology to tailor an appropriate plan for each patient.

Reimbursement claims with a date of service on or after October 1, 2015 require the use of ICD-10-CM codes.

Clinical Advice & FAQs

Billing Guidance

Is C81.30 a billable ICD-10 code?
Yes, C81.30 is a specific, billable code that can be used to indicate a diagnosis for reimbursement purposes.

Documentation

How do I report C81.30?
Clinical documentation must specify the nature of Lymphocyte depleted Hodgkin lymphoma, unspecified site and any associated comorbidities for accurate reporting.

Cite this Clinical Reference